Company
Liminatus Pharma, Inc. (LIMN)
Standardized SEC financial data for Liminatus Pharma, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001971387 · NASDAQ · Biological Products, (No Diagnostic Substances).
Return on equity
104.0%
Free cash flow
-$10.0M
Current ratio
0.05×
EPS (diluted)
$-0.43
Income statement
| USD | FY2024 | FY2025 |
|---|---|---|
| R&D expense | $2.7M | — |
| SG&A expense | $645K | $3.0M |
| Operating income | -$3.3M | -$3.0M |
| Net income | -$3.5M |
Balance sheet
| USD | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total current assets | — | $5.3M | $501K |
| Property, plant & equipment | — | $941 | $12K |
| Total assets | — | $5.4M |
Cash flow
| USD | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$1.5M | -$10.0M |
| Capital expenditures | — | $13K |
| Free cash flow | — | -$10.0M |
| Investing cash flow | -$2.9M |
Get LIMN data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/LIMN/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/LIMN/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"